Clinical trial
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study)
NCT02158533 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study)
- Lead sponsor
- Alkermes, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- December 31, 2015
- Enrollment
- 385 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.